| Mar'20 | Sep'19 | Jun'19 | Mar'19 | Sep'18 | Jun'18 | |
|---|---|---|---|---|---|---|
License revenue | ||||||
- | 0 | - | - | - | - | |
Operating expenses: | ||||||
Cost of license revenue | ||||||
- | 0 | - | - | - | - | |
Research and development | ||||||
0 | 0 | - | 0 | 0 | - | |
General and administrative | ||||||
0 | 0 | - | 0 | 0 | - | |
Total operating expenses | ||||||
0 | 0 | - | 0 | 0 | - | |
Loss from operations | ||||||
0 | 0 | - | 0 | 0 | - | |
Other income (expense), net: | ||||||
Interest income | ||||||
0 | 0 | - | 0 | 0 | - | |
Interest expense | ||||||
0 | 0 | - | 0 | 0 | - | |
Loss from ML Bio asset acquisition | ||||||
- | 0 | - | - | - | - | |
Share in net loss of an equity method investment | ||||||
- | 0 | - | 0 | - | - | |
LEO call option income (expense) | ||||||
- | 0 | - | - | - | - | |
Other income (expense) | ||||||
0 | 0 | - | 0 | 0 | - | |
Total other income (expense), net | ||||||
0 | 0 | - | 0 | 0 | - | |
Net loss | ||||||
0 | 0 | - | 0 | 0 | - | |
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | ||||||
0 | 0 | - | 0 | 0 | - | |
Net loss attributable to common stockholders of BridgeBio | ||||||
0 | 0 | - | 0 | 0 | - | |
Net loss per share, basic and diluted | ||||||
-0.78 | -0.51 | - | -0.66 | -0.52 | - | |
Weighted-average shares used in computing net loss per share, basic and diluted | ||||||
117,803,438 | 117,071,188 | - | 92,330,072 | 60,950,572 | - | |
BridgeBio Pharma LLC | ||||||
Research and development | ||||||
- | - | 0 | - | - | 0 | |
General and administrative | ||||||
- | - | 0 | - | - | 0 | |
Total operating expenses | ||||||
- | - | 0 | - | - | 0 | |
Loss from operations | ||||||
- | - | 0 | - | - | 0 | |
Interest income | ||||||
- | - | 0 | - | - | 0 | |
Interest expense | ||||||
- | - | 0 | - | - | 0 | |
Loss from PellePharm | ||||||
- | - | 0 | - | - | - | |
LEO call option income (expense) | ||||||
- | - | 0 | - | - | - | |
Other income (expense) | ||||||
- | - | 0 | - | - | 0 | |
Total other income (expense), net | ||||||
- | - | 0 | - | - | 0 | |
Net loss and comprehensive loss | ||||||
- | - | 0 | - | - | 0 | |
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | ||||||
- | - | 0 | - | - | 0 | |
Net loss and comprehensive loss attributable to BridgeBio | ||||||
- | - | 0 | - | - | 0 | |
Cumulative returns on redeemable convertible preferred units (Series A, Series B and Series C) | ||||||
- | - | - | - | - | 0 | |
Net loss attributable to redeemable founder units and redeemable common units | ||||||
- | - | 0 | - | - | 0 | |
Net loss per unit attributable to redeemable founder unitholders and redeemable common unitholders, basic and diluted | ||||||
- | - | -3.46 | - | - | -1.71 | |
Total weighted-average redeemable founder units and redeemable common units used in computing net loss per unit, basic and diluted | ||||||
- | - | 19,033,838 | - | - | 17,821,117 | |